Subscribe For Free! Sign up to receive the print magazine six times per year and the e-mail newsletter twice a month. Learn more >
A cloud of uncertainty hangs over the pharmaceutical industry in Puerto Rico following the expiration of tax incentives from Section 936 of the U.S. Internal Revenue Code. Could emerging combinations of biopharmaceuticals and medical devices provide a silver lining? A report from Interphex Puerto Rico.
Pharmaceutical firms seek packaging line improvements to cut costs, biologics present packaging challenges, and medical device growth is driven by aging baby boomers. These treatment advances bode well for the healthcare/life sciences packaging community. Packaging materials need to offer protection from point of manufacture to the “last mile” where healthcare products reach a patient. Packaging materials must provide barriers for moisture, oxygen, light and heat, and they may include overt and/or covert security measures to combat counterfeiting and diversion. Equipment will need to package products more efficiently, be validatable and versatile.
To meet the growing demand for pediatric and adult vaccines, GSK is investing more than 500 million euros in a vaccine manufacturing plant to increase production in formulation, filling, freeze-drying, and packaging.
Package: Duoject’s Inter-Vial is a packaging system that contains, mixes, and injects medicine in a single unit. This medical device-drug package hybrid allows a health professional to reconstitute a lyophilized (freeze-dried) drug by mixing it with a liquid diluent. The drug is then injected, using the same device. The Inter-Vial consists of several intricately molded plastic pieces that have to be snapped or screwed together.
